Delving into the Latest Updates on Beijing Gene Key Life Technology Co., Ltd with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Endocrinology and Metabolic Disease

Fusion protein

iNKT cell therapy

CAR-NKT

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

iNKT cell therapy	1
CAR-NKT	1
Fusion protein	1

Top 5 Target	Count

GPC3 x IL-15	1
GPC3(Glypican-3)	1

Primary objective: To evaluate the safety and tolerability of multiple administrations of GKL-006 injection in patients with unresectable hepatocellular carcinoma. Secondary objective: To evaluate the PK and PD parameters of multiple administrations of GKL-006 injection. To evaluate the preliminary efficacy of multiple administrations of GKL-006 injection in the treatment of HCC.

Start Date-

Sponsor / Collaborator

Beijing Gene Key Life Technology Co., Ltd

CTR20240402

/ RecruitingPhase 1

GKL-006 注射液联合经肝动脉化疗栓塞术（TACE）对比单纯TACE 用于不可切除的肝细胞癌患者中开放、对照单次给药的安全性、耐受性和 PK/PD 的 I 期临床试验

[Translation] Phase I clinical trial of the safety, tolerability and PK/PD of GKL-006 injection combined with transarterial chemoembolization (TACE) versus TACE alone in patients with unresectable hepatocellular carcinoma

评价 GKL-006 注射液联合 TACE 在不可切除的肝细胞癌患者中单次给药的安全性和耐受性，以确定联合方案的最大耐受剂量（MTD），并评价单次给药治疗的剂量限制性毒性（DLT）。

[Translation]

To evaluate the safety and tolerability of a single dose of GKL-006 injection combined with TACE in patients with unresectable hepatocellular carcinoma, to determine the maximum tolerated dose (MTD) of the combination regimen, and to evaluate the dose-limiting toxicity (DLT) of single-dose treatment.

Start Date06 Apr 2024

Sponsor / Collaborator

Beijing Gene Key Life Technology Co., Ltd

NCT05962450

/ RecruitingPhase 2IIT

An Open Label, Randomized, Controlled, Clinical Trial of Adoptive Autologous Invariant Natural Killer T Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

The goal of this clinical trial is to explore the efficacy and safety of autologous iNKT cells in patients with progressed hepatocellular carcinoma (HCC) after treatment with PD-1 antibody. The main question it aims to answer are:
the efficacy of autologous iNKT cells in patients with progressed HCC after treatment with PD-1 antibody.
the safety of autologous iNKT cells in patients with progressed HCC after treatment with PD-1 antibody.
Participants will be randomized 1:1 to receive Regorafenib + PD-1 + iNKT cells (RPI group) or the treatment of Regorafenib + PD-1 (RP group).
Researchers will compare RPI group and RP group to see whether the iNKT cells can achieve a better therapeutic effect on HCC patients with PD-1 resistance.

Start Date26 Oct 2023

Sponsor / Collaborator

Beijing YouAn Hospital

[+1]

100 Clinical Results associated with Beijing Gene Key Life Technology Co., Ltd

Login to view more data

0 Patents (Medical) associated with Beijing Gene Key Life Technology Co., Ltd

Login to view more data

100 Deals associated with Beijing Gene Key Life Technology Co., Ltd

Login to view more data

100 Translational Medicine associated with Beijing Gene Key Life Technology Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 1 Clinical

Login to view more data